<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01151683</url>
  </required_header>
  <id_info>
    <org_study_id>MG600</org_study_id>
    <nct_id>NCT01151683</nct_id>
  </id_info>
  <brief_title>Effects of Magnesium Supplementation on Vascular Structure and Function in Hypertensive Patients</brief_title>
  <acronym>MG600</acronym>
  <official_title>Effects of Magnesium Supplementation on Vascular Structure and Function in Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rio de Janeiro State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rio de Janeiro State Research Supporting Foundation (FAPERJ)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rio de Janeiro State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Magnesium has been the target for many experimental and clinical studies due to&#xD;
      the negative correlation between its serum and intracellular levels and the prevalence of&#xD;
      hypertension and other cardiovascular diseases.&#xD;
&#xD;
      Objective: To evaluate the effects of magnesium supplementation in hypertensive patients who&#xD;
      are under diuretic treatment, including correlation of clinical and nutritional parameters&#xD;
      with structural and functional aspects of the macrocirculation.&#xD;
&#xD;
      Methods: A prospective, randomized, double blind, placebo controlled study will be performed&#xD;
      in hypertensive patients, aged between 40 and 65 years-old, in regular use of thiazidic&#xD;
      diuretic as antihypertensive monotherapy,. The patients will be divided in two main groups&#xD;
      according to supplementation with placebo or magnesium chelate 300mg twice a day (total of&#xD;
      600mg magnesium element per day). Before and after 3 and 6 months of supplementation, the&#xD;
      patients will be submitted to clinical and nutritional evaluation, biochemical analysis,&#xD;
      including intracellular magnesium measurement, and study of the macrocirculation with&#xD;
      ambulatory blood pressure monitoring, analysis of flow-mediated dilation of brachial artery,&#xD;
      measurement of carotid intima-media thickness, and carotid-femoral and carotid-radial pulse&#xD;
      wave velocity to estimate central and peripheral arterial stiffness.&#xD;
&#xD;
      Analysis: Data will be expressed as mean±epm. Statistical analysis will be performed using&#xD;
      software Prism® (GraphPad, version 5.0). Continuous variables in each group will be compared&#xD;
      using &quot;t test&quot;, and P&lt;0.05 will be considered statistically significant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to evaluate whether magnesium supplementation is&#xD;
      associated with improved blood pressure control and whether it has beneficial effects on the&#xD;
      vascular structure and function in non-diabetic hypertensive patients who are receiving r&#xD;
      diuretic therapy.&#xD;
&#xD;
      Patients will be evaluated in a prospective, randomized, double-blind study and will be&#xD;
      admitted to the study if they reach all the inclusion criteria and no exclusion criteria.&#xD;
&#xD;
      In this study, magnesium chelate was chosen because of its better absorption rate. The&#xD;
      dosages are different in many protocols but in this project the patients will receive 600 mg&#xD;
      of magnesium element daily divided in 300 mg twice a day. The patients will be divided in two&#xD;
      main groups according to supplementation with placebo or magnesium chelate 300mg twice a day&#xD;
      (total of 600mg magnesium element per day). Before and after 3 and 6 months of&#xD;
      supplementation, the patients will be submitted to clinical and nutritional evaluation,&#xD;
      biochemical analysis, including intracellular magnesium measurement, and study of the&#xD;
      macrocirculation with ambulatory blood pressure monitoring, analysis of flow-mediated&#xD;
      dilation of brachial artery, measurement of carotid intima-media thickness, and&#xD;
      carotid-femoral and carotid-radial pulse wave velocity to estimate central and peripheral&#xD;
      arterial stiffness.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of vascular function</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of vascular structure and blood pressure</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Hypertension</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Magnesium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Magnesium chelate 600 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 4 capsules per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>magnesium</intervention_name>
    <description>Magnesium chelate, 300mg (2 capsules of 150mg) twice a day, per oral Total of 600mg per day</description>
    <arm_group_label>Magnesium</arm_group_label>
    <other_name>Mg supplement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Two capsules of placebo per oral twice a day</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Inactive component</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women aged between 40 and 65 years-old&#xD;
&#xD;
          -  Hypertension with mild blood pressure elevation:&#xD;
&#xD;
               -  Systolic BP between 140 and 159mmHg AND/OR&#xD;
&#xD;
               -  Diastolic BP between 90 and 99 mmHg&#xD;
&#xD;
          -  Antihypertensive monotherapy with daily use of thiazidic diuretic, at least in the&#xD;
             last 30 days&#xD;
&#xD;
          -  Signature of the Informed Consent by the patient or his legal representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidences for secondary hypertension&#xD;
&#xD;
          -  Hypertension in stage 2, SBP ≥ 160mmHg and/or DBP ≥ 100mmHg, before the beginning of&#xD;
             supplementation&#xD;
&#xD;
          -  Blood pressure &gt; 180 x 100 mmHg in any phase of the study&#xD;
&#xD;
          -  Body mass index &gt; 35 kg/m2&#xD;
&#xD;
          -  Diabetes Mellitus&#xD;
&#xD;
          -  Renal disease presenting glomerular filtration rate &lt; 60ml/min&#xD;
&#xD;
          -  Coronary artery disease clinically evident with previous episode of myocardial&#xD;
             infarction and/or myocardial revascularization&#xD;
&#xD;
          -  Clinical signs of heart failure&#xD;
&#xD;
          -  History of stroke&#xD;
&#xD;
          -  Any condition, disease or therapy that, under investigator's opinion, may influence&#xD;
             objectives, results, or put in risk the safety of the patients.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients should not be taking any mineral or vitamin supplements&#xD;
&#xD;
          -  Gastrointestinal conditions&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario F Neves, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State University of Rio de Janeiro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Medicine, State University of Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20551030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>June 25, 2010</study_first_submitted>
  <study_first_submitted_qc>June 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2010</study_first_posted>
  <last_update_submitted>January 4, 2013</last_update_submitted>
  <last_update_submitted_qc>January 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rio de Janeiro State University</investigator_affiliation>
    <investigator_full_name>Mario Fritsch Neves</investigator_full_name>
    <investigator_title>Full Professor</investigator_title>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>endothelial dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

